Parvus Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
555 Airport Blvd Ste 350, Burlingame, Ca...Phone Number
(403) 708-3401Website
www.parvustherapeutics.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Parvus Therapeutics
Parvus Therapeutics Inc. is a privately-held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics targeting autoimmune diseases. Navacims were discovered by Pere Santamaria, M.D., Ph.D. Chief Scientific Officer and Founder of Parvus, Julia McFarlane/Diabetes Canada Professor of the Cumming School of Medicine at the University of Calgary.Explore more
Parvus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Parvus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Parvus Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Parvus Therapeutics launches new products
Check if Parvus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Parvus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Parvus Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Parvus Therapeutics
Click to see if Parvus Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Parvus Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Parvus Therapeutics
Compare insights from companies similar to Parvus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Parvus Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Parvus Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Parvus Therapeutics.
Parvus Therapeutics Tech Stack
A closer look at the technologies used by Parvus Therapeutics
Parvus Therapeutics News & Media
Parvus Therapeutics Reports Positive Phase 1 Results for Lead Autoimmune Treg Therapy, PVT201
PVT201 demonstrated favorable safety, predictable pharmacokinetics, and on-target pharmacodynamic activity in first-in-human study. [PR.com]Parvus Announces Achievement of First Milestone from its Collaboration Agreement with AbbVie to Develop IBD Therapies Based on the Parvus Nanomedicine Platform Technology
IND-enabling nonclinical and manufacturing activities executed by Parvus met prospective criteria resulting in the first milestone payment from AbbVie. [PR.com]Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical
New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. [PR.com]Parvus Therapeutics Has Received Orphan Drug Designation for Primary Biliary Cholangitis and Human Research Ethics Committee Approval to to Begin Clinical Testing
Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human Phase I clinical trial. “Orphan Drug Designation and HREC approval are the latest development milestones which represent [PR.com]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Parvus Therapeutics
Sign Up For FreeTo access detailed company insights
Parvus Therapeutics Inc. is a privately-held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics targeting autoimmune diseases. Navacims were discovered by Pere Santamaria, M.D., Ph.D. Chief Scientific Officer and Founder of Parvus, Julia McFarlane/Diabetes Canada Professor of the Cumming School of Med... Read More
